We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

66 hedge funds and large institutions have $81.2M invested in LENZ Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

11% more capital invested

Capital invested by funds: $72.9M → $81.2M (+$8.38M)

6% more funds holding

Funds holding: 62 → 66 (+4)

0.38% more ownership

Funds ownership: 7.31% → 7.68% (+0.38%)

0% more call options, than puts

Call options by funds: $1.53M | Put options by funds: $1.53M

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
66
Holders Change
+4
Holders Change %
+6.45%
% of All Funds
1.04%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
22
Reduced
14
Closed
11
Calls
$1.53M
Puts
$1.53M
Net Calls
+$3K
Net Calls Change
+$18K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.43M
2
PM
Prosight Management
Texas
+$2.35M
3
State Street
State Street
Massachusetts
+$1M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$773K
5
CA
CHI Advisors
New York
+$659K

Top Sellers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
-$2.38M
2
LCM
Laurion Capital Management
New York
-$1.4M
3
Verition Fund Management
Verition Fund Management
Connecticut
-$1.11M
4
WSL
Western Standard LLC
California
-$914K
5
Morgan Stanley
Morgan Stanley
New York
-$378K
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
51
California State Teachers Retirement System (CalSTRS)
California
$24.2K +$26.6K +1,332 New
Royal Bank of Canada
52
Royal Bank of Canada
Ontario, Canada
$21K +$23.2K +1,159 +115,900%
Barclays
53
Barclays
United Kingdom
$14.7K -$50.5K -2,525 -76%
TRCT
54
Tower Research Capital (TRC)
New York
$8.3K -$4.63K -232 -34%
Lazard Asset Management
55
Lazard Asset Management
New York
$7K +$500 +25 +6%
AB
56
Amalgamated Bank
New York
$7K +$7.77K +389 New
Legal & General Group
57
Legal & General Group
United Kingdom
$6.96K +$7.63K +382 New
AIP
58
Ameritas Investment Partners
Nebraska
$6.02K +$6.61K +331 New
Osaic Holdings
59
Osaic Holdings
Arizona
$3.48K -$5K -250 -57%
Fidelity Investments
60
Fidelity Investments
Massachusetts
$3.37K +$3.7K +185 New
NA
61
Nordwand Advisors
Pennsylvania
$2.6K – – –
CUAMC
62
China Universal Asset Management Company
China
$1.98K -$80 -4 -4%
SOW
63
State of Wyoming
Wyoming
$663 +$220 +11 +44%
FDCDDQ
64
Federation des caisses Desjardins du Quebec
Quebec, Canada
$520 – – –
KPF
65
K2 Principal Fund
Ontario, Canada
– -$2.38M -138,517 Closed
Susquehanna International Group
66
Susquehanna International Group
Pennsylvania
– -$181K -9,064 Closed
Jane Street
67
Jane Street
New York
– -$136K -7,954 Closed
Marshall Wace
68
Marshall Wace
United Kingdom
– -$100K -5,844 Closed
GCP
69
GSA Capital Partners
United Kingdom
– -$98K -5,726 Closed
HF
70
HRT Financial
New York
– -$47K -2,785 Closed
CC
71
Cannell Capital
Wyoming
– -$35.1K -2,044 Closed
Squarepoint
72
Squarepoint
New York
– -$34.6K -2,016 Closed
QT
73
Quantbot Technologies
New York
– -$3.92K -229 Closed
PCFFS
74
Pacific Center for Financial Services
California
– -$1.84K -107 Closed
1 2
3

LENZ Hedge Fund Activity: Q2 2023 in Review

66 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2023, worth a combined $81.2M — up 11% from $72.9M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new LENZ positions and 11 closed out — a net gain of 4 holders — while 22 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $3.43M. The largest seller was K2 Principal Fund, exiting entirely with an estimated $2.38M sold.

  • 66 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2023, up from 62 in Q1 2023.
  • Funds reported $81.2M of LENZ Therapeutics stock for Q2 2023, up 11% quarter-over-quarter.
  • 15 funds opened new LENZ Therapeutics positions in Q2 2023 and 11 closed out, a net change of +4 holders.
  • The largest LENZ Therapeutics buyer in Q2 2023 was BlackRock, an estimated $3.43M added.
  • The largest LENZ Therapeutics seller in Q2 2023 was K2 Principal Fund, an estimated $2.38M sold.

Based on aggregated 13F filings for Q2 2023.